| 1 | 22512618 | Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). | J Med Chem | 2012 May 10 |
1 |
| 2 | 26165074 | [Vonoprazan: a novel potassium-competitive acid blocker]. | Nihon Rinsho | 2015 Jul |
2 |
| 3 | 26369775 | The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. | Clin Pharmacokinet | 2016 Apr |
6 |
| 4 | 26559637 | Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. | Aliment Pharmacol Ther | 2016 Jan |
1 |
| 5 | 26991399 | Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. | Aliment Pharmacol Ther | 2016 May |
2 |
| 6 | 27414183 | In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. | Xenobiotica | 2017 Dec |
10 |
| 7 | 27465369 | Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. | Drug Metab Dispos | 2016 Oct |
1 |
| 8 | 27891632 | Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. | Aliment Pharmacol Ther | 2017 Jan |
1 |
| 9 | 27928738 | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | Clin Drug Investig | 2017 Mar |
2 |
| 10 | 28190016 | Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. | Digestion | 2017 |
3 |
| 11 | 28875498 | Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. | Clin Pharmacol Ther | 2018 May |
3 |
| 12 | 28986609 | Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. | Eur J Clin Pharmacol | 2018 Jan |
1 |
| 13 | 29057719 | Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. | Xenobiotica | 2018 Nov |
1 |
| 14 | 29393198 | Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study. | Digestion | 2018 |
3 |
| 15 | 30361928 | In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel. | Eur J Drug Metab Pharmacokinet | 2019 Apr |
6 |
| 16 | 30562434 | Potassium-competitive acid blocker. | Nihon Rinsho | 2016 Aug |
1 |
| 17 | 30755541 | Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis. | Med Sci Monit | 2019 Feb 13 |
1 |
| 18 | 30845361 | Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. | Br J Clin Pharmacol | 2019 Jul |
3 |
| 19 | 30897577 | Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux. | Digestion | 2020 |
3 |
| 20 | 30993551 | Inhibitory Effect of Vonoprazan on the Metabolism of [<sup>14</sup>C]Prasugrel in Human Liver Microsomes. | Eur J Drug Metab Pharmacokinet | 2019 Oct |
6 |
| 21 | 31178490 | Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. | Intern Med | 2019 Sep 1 |
2 |
| 22 | 31320930 | Current status of first- and second-line <i>Helicobacter pylori</i> eradication therapy in the metropolitan area: a multicenter study with a large number of patients. | Therap Adv Gastroenterol | 2019 |
1 |
| 23 | 31679094 | Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis. | Esophagus | 2020 Jan |
2 |
| 24 | 32062650 | The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease. | Digestion | 2021 |
1 |
| 25 | 32116727 | Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan <i>In Vitro</i> and <i>In Vivo</i>. | Front Pharmacol | 2020 |
4 |
| 26 | 32118778 | Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies. | Medicine (Baltimore) | 2020 Feb |
1 |
| 27 | 32993151 | Effect of Antibiotic Susceptibility and <i>CYP3A4/5</i> and <i>CYP2C19</i> Genotype on the Outcome of Vonoprazan-Containing <i>Helicobacter pylori</i> Eradication Therapy. | Antibiotics (Basel) | 2020 Sep 26 |
6 |
| 28 | 32998241 | The Potential Benefits of Vonoprazan as <i>Helicobacter pylori</i> Infection Therapy. | Pharmaceuticals (Basel) | 2020 Sep 28 |
2 |
| 29 | 32999170 | Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients. | Biol Pharm Bull | 2020 |
1 |
| 30 | 33305731 | Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study. | Pharmazie | 2020 Oct 1 |
1 |
| 31 | 33333602 | Editorial: "Stardust gastric mucosa" - A novel and consistent marker of vonoprazan safety during follow-up? | Aliment Pharmacol Ther | 2021 Jan |
1 |
| 32 | 33693287 | Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y<sub>12</sub> Assay in Patients With Coronary Artery Disease. | Circ Rep | 2020 Dec 18 |
2 |
| 33 | 34059932 | Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia. | Eur J Clin Pharmacol | 2021 Jul |
2 |
| 34 | 34176835 | Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan. | Intern Med | 2022 Jan 1 |
1 |
| 35 | 34484992 | Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan. | J Gen Fam Med | 2021 Sep |
2 |
| 36 | 34867368 | Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. | Front Pharmacol | 2021 |
1 |
| 37 | 35004113 | Vonoprazan-associated long QT syndrome. | J Gen Fam Med | 2022 Jan |
1 |
| 38 | 35214161 | Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery. | Pharmaceutics | 2022 Feb 16 |
2 |
| 39 | 35226174 | Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. | J Gastroenterol | 2022 Apr |
1 |
| 40 | 35386943 | Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. | J Scleroderma Relat Disord | 2022 Feb |
4 |
| 41 | 35571388 | Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. | Ann Transl Med | 2022 Apr |
2 |